目的观察和评价扶正散结汤治疗晚期原发性肝癌的临床疗效和不良反应。方法 56例原发性晚期肝癌患者均经CT、B超、甲胎蛋白或肝组织学检查确诊。扶正散结汤每日口服3次,4周为1个周期,共治疗2个周期。结果 56例患者均可评价,完全缓解2例,部分缓解27例,稳定10例,进展17例,患者近期有效率为51.8%,疾病进展时间7.4个月,中位生存期12.8个月,1年生存率为53.6%。中医分型疗效分析:显效率为51.8%,总有效率为69.6%;生活质量提高率为76.8%,稳定率为14.2%;体质量增加率为73.2%,稳定率为19.6%。主要不良反应有血小板减少(3.6%),心电图异常(3.6%),白细胞减少(1.8%),但均可以耐受。结论扶正散结汤治疗晚期原发性肝癌有较好的临床疗效,可提高患者生活质量,延长生存期,增强免疫功能,缩小瘤体。 Objective To observe and evaluate the clinical efficacy and adverse reactions of Fuzheng Sanjie Decoction in the treatment of advanced primary liver cancer. Methods 56 patients with primary liver cancer were diagnosed by CT, B ultrasound, AFP or liver histology. Fuzheng Sanjie oral daily oral 3 times, 4 weeks for a cycle, a total of 2 cycles. Results Fifty-six patients were evaluated. Complete remission was achieved in 2 cases, partial remission in 27 cases, stable in 10 cases and progression in 17 cases. The effective rate was 51.8%, the disease progression time was 7.4 months, the median survival time was 12.8 months, 1 The annual survival rate was 53.6%. TCM analysis of the curative effect: the markedly effective rate was 51.8%, the total effective rate was 69.6%; the quality of life improvement rate was 76.8%, the stability rate was 14.2%; the body weight increase rate was 73.2% and the stability rate was 19.6%. The main adverse reactions were thrombocytopenia (3.6%), abnormal electrocardiogram (3.6%) and leucopenia (1.8%), all of which were tolerable. Conclusions Fuzheng Sanjie Decoction can treat advanced primary hepatocellular carcinoma with better clinical curative effect, which can improve patients’ quality of life, prolong survival, enhance immune function and reduce tumor size.